Managing Hepatitis C: The High Price of Not Prioritizing Therapy
Hepatitis C Virus (HCV) is a chronic infection that causes severe liver disease and is the leading cause for liver transplants. Until recently, HCV has been difficult to treat and nearly impossible to cure with existing therapies. New prescription therapies for hepatitis C have improved cure rates. However, they come at a significantly increased cost. The impact of the increase highlights the need for budget impact modeling for new, innovative therapies. This presentation outlines many of the financial challenges these new therapies present and how payers can mitigate these issues.